Two wearable devices created by Toronto-based Vielight Inc. appear to be demonstrate promising outcomes for patients affected by Alzheimer’s disease or dementia, according to a randomized placebo-controlled pilot study conducted last year.
Using the firm’s patented Vielight 810 Infrared and patent-pending Vielight Neuro wearable devices, the study presented the arrest or reversal in the decline of Alzheimer’s Disease. The patients used the ‘Neuro’ for 20 minutes once or twice a week and the ‘Vielight 810’ every day for 25 minutes. The results of this pilot study are significant and strongly suggest that the treatment for people with moderate-severe cognitive impairment can result in significant clinical improvements.
The technology involved the science of low level light therapy (LLLT) or photobiomodulation therapy (PBMT), a process in which exposure to low-level light or light emitting diodes stimulate cellular function leading to beneficial clinical effects.
Vielight specializes in developing wearable photobiomodulation therapy (PBMT) devices to improve well-being. Their devices are used in research projects in institutions globally, including Harvard Medical School and Boston University. After 10 years production, Vielight has more than 15,000 devices in the field, used by consumers around the world with no reported major side effects.